News

CGeneTech Partners with Yunxuan Pharmaceuticals for CXCR4 Antagonist Broad Distribution

  • Categories:Company News
  • Author: BioBAY
  • Origin:
  • Time of issue:2020-04-16
  • Views:0

(Summary description)CGeneTech, a company focused on both internal R&D and outbound alliances, recently announced that it has signed an exclusive collaboration and license agreement with Yunxuan Pharmaceuticals to acquire exclusive global development and commercialization rights for one of its preclinical chemokine receptor type 4 (CXCR4) antagonists.

CGeneTech Partners with Yunxuan Pharmaceuticals for CXCR4 Antagonist Broad Distribution

(Summary description)CGeneTech, a company focused on both internal R&D and outbound alliances, recently announced that it has signed an exclusive collaboration and license agreement with Yunxuan Pharmaceuticals to acquire exclusive global development and commercialization rights for one of its preclinical chemokine receptor type 4 (CXCR4) antagonists.

  • Categories:Company News
  • Author: BioBAY
  • Origin:
  • Time of issue:2020-04-16
  • Views:0

CGeneTech, a company focused on both internal R&D and outbound alliances, recently announced that it has signed an exclusive collaboration and license agreement with Yunxuan Pharmaceuticals to acquire exclusive global development and commercialization rights for one of its preclinical chemokine receptor type 4 (CXCR4) antagonists.

CXCR4 belongs to a family of cytokine receptors that form the?CXCR4/SDF-1 signaling axis with its natural ligand, stromal cell-derived factor-1 (SDF-1), and plays an important role in the infiltration and metastasis of malignant tumors, migration and homing of stem cells, the immune and inflammatory response of the body, and HIV virus infection. According to the cutting-edge international research, this selective antagonist can be applied in the following therapeutic areas: (i) overcoming malignant tumor brain metastasis, overcoming primary and secondary tumor drug resistance in combination with immunotherapy, reducing tumor stem cell escape in combination with targeted angiogenic drugs, etc., and reducing tumor recurrence in combination with radiotherapy and chemotherapy. ②As a small molecule stem cell mobilizer, it is used in first-line consolidation and second-line salvage autologous hematopoietic stem cell transplantation for patients with multiple myeloma and non-Hodgkin's lymphoma. ③For the treatment of WHIM syndrome, an inherited primary autoimmune rare disease, for which there is still no effective therapeutic drug approved.

Professor Xiaohu Zhang, founder of Yunxuan Pharmaceuticals, said, "As an old classmate of the same year in the chemistry department of Peking University, I am very familiar with the entrepreneurial team of CGeneTech, and I most appreciate the execution and control of the project by Torping Ding and Qiang Yu. I believe they can take this compound I designed and synthesized, continue to nurture it like a child, and eventually turn it into a good drug."

Dr. Qiang Yu, CEO of CGeneTech, thanked his old classmate for his trust and said, "Through preclinical head-to-head experimental comparisons, we believe that Professor Zhang's compound has best-in-class or first-in-class potential in multiple therapeutic areas, which is in line with CGeneTech's R&D philosophy We are in the process of completing our diabetes pipeline. After improving our pipeline in diabetes, we have recently started to develop our portfolio in antineoplastic and rare diseases. With the introduction of this variety, it is just as well that the whole package is vivid with the fall of Tianyuan."

It is reported that according to the terms of the agreement, CGeneTech will pay back to Yunxuan Pharmaceuticals in stages in the form of advance payment, R&D milestone payment and sales commission.

The

The listing application of Shengshi Tyco's new hypoglycemic drug Shenggliptin was accepted

Today, Shengshi Tyco has accepted the marketing application (NDA) of Shenggliptin, a DPP-4 inhibitor, submitted to the National Drug Administration (NMPA) for the treatment of type 2 diabetes.
2023-02-02
Quantity

"Quantity" Half Achieves Double Prosperity: Tyco's Class 1 New Hypoglycemic Drug Shenggliptin Uncovers Blindness Data

Today, Shengshi Tyco has completed a key clinical study on a class 1 new hypoglycemic drug under development: phase III clinical trial of DPP-4 inhibitor shenggliptin in the treatment of type 2 diabetes. A dose of 50mg can reach the preset end point of the trial. A therapeutic dose of "half the dose" will further improve the safety of this drug and is expected to become the best hypoglycemic drug in the same class.
2022-10-17

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO